99 related articles for article (PubMed ID: 20882882)
1. Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells.
Chao KC; Chang CC; Yen MS; Wang PH
Eur J Gynaecol Oncol; 2010; 31(4):402-10. PubMed ID: 20882882
[TBL] [Abstract][Full Text] [Related]
2. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Chikamatsu K; Ishii H; Murata T; Sakakura K; Shino M; Toyoda M; Takahashi K; Masuyama K
Cancer Sci; 2013 Nov; 104(11):1468-75. PubMed ID: 23992541
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Hauswald S; Duque-Afonso J; Wagner MM; Schertl FM; Lübbert M; Peschel C; Keller U; Licht T
Clin Cancer Res; 2009 Jun; 15(11):3705-15. PubMed ID: 19458058
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
[TBL] [Abstract][Full Text] [Related]
5. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
7. Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors.
Zhu K; Qu D; Sakamoto T; Fukasawa I; Hayashi M; Inaba N
Arch Gynecol Obstet; 2008 Jan; 277(1):15-9. PubMed ID: 17680259
[TBL] [Abstract][Full Text] [Related]
8. Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
De los Santos M; Martínez-Iglesias O; Aranda A
Endocr Relat Cancer; 2007 Dec; 14(4):1021-8. PubMed ID: 18045953
[TBL] [Abstract][Full Text] [Related]
9. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization.
Kim H; Kim SN; Park YS; Kim NH; Han JW; Lee HY; Kim YK
Int J Oncol; 2011 Mar; 38(3):807-12. PubMed ID: 21170509
[TBL] [Abstract][Full Text] [Related]
11. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Wu CP; Hsiao SH; Su CY; Luo SY; Li YQ; Huang YH; Hsieh CH; Huang CW
Biochem Pharmacol; 2014 Dec; 92(4):567-76. PubMed ID: 25450670
[TBL] [Abstract][Full Text] [Related]
12. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
13. 18β-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines.
Lee CS; Yang JC; Kim YJ; Jang ER; Kim W; Myung SC
Eur J Pharmacol; 2010 Dec; 649(1-3):354-61. PubMed ID: 20868669
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
16. Effect of sodium butyrate on doxorubicin resistance and expression of multidrug resistance genes in thyroid carcinoma cells.
Massart C; Poirier C; Fergelot P; Fardel O; Gibassier J
Anticancer Drugs; 2005 Mar; 16(3):255-61. PubMed ID: 15711177
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Díaz-Núñez M; Díez-Torre A; De Wever O; Andrade R; Arluzea J; Silió M; Aréchaga J
BMC Cancer; 2016 Aug; 16(1):667. PubMed ID: 27549189
[TBL] [Abstract][Full Text] [Related]
18. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
20. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.
Nakayama K; Kanzaki A; Ogawa K; Miyazaki K; Neamati N; Takebayashi Y
Int J Cancer; 2002 Oct; 101(5):488-95. PubMed ID: 12216079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]